RxDoctor Payments Data

Catherine Rossi, MD

Family Medicine · Melbourne, FLNPI 1841274883

Payments from drug & device makers

$1,007in general payments, 2019–2025

Across 40 payments — averaging $25.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$343
  • Genentech USA, Inc.$138
  • Sunovion Pharmaceuticals Inc.$121
  • E.r. Squibb & Sons, L.L.C.$71
  • Astellas Pharma US Inc$63
  • AstraZeneca$44
  • plus $227 from 8 others

What the payments were for

  • Food & beverage$1,007100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,007 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$154,066
Medicare patients
1,062
Services billed
2,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$49,658
XareltoRivaroxaban24$21,345
EliquisApixaban18$18,881
Levothyroxine Sodium241$4,432
Rosuvastatin Calcium195$4,159
Enalapril Maleate149$3,964
Venlafaxine Hcl ErVenlafaxine Hcl26$3,177
Amlodipine Besylate265$2,815
Metoprolol Succinate106$2,725
Atorvastatin Calcium200$2,599
SynthroidLevothyroxine Sodium29$2,543
Valsartan66$2,503
Losartan Potassium149$2,442
Omeprazole105$2,067
Simvastatin109$2,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$27$49,65833 claims
PfizerEliquis$32$18,88118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →